Hanlin Xu, MD

Articles by Hanlin Xu, MD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

ByDapeng Wu, MD, PhD,Juanjuan Cui, MD,Wenjing Zhum MD, PhD,Tao Qin, MD,Hanlin Xu, MD

March 20th 2026

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection.

Latest Updated Articles

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer
March 20th 2026

Hanlin Xu, MD

Articles by Hanlin Xu, MD

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Ruxolitinib Tablets for Hematologic Malignancies

How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?

Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer

SLN Surgery Omission Does Not Increase Radiotherapy Use in Breast Cancer

Treatment of Patients with FLT3-ITD+ Acute Myeloid Leukemia in Three Phases